Top

Published in:

01-11-2014 | Research Article

Melanoma differentiation-associated gene-7/interleukin-24 as a potential prognostic biomarker and second primary malignancy indicator in head and neck squamous cell carcinoma patients

Authors: Lin Wang, Zhien Feng, Huanhuan Wu, Shuai Zhang, Yinfei Pu, Huan Bian, Yixiang Wang, Chuanbin Guo

Published in: Tumor Biology | Issue 11/2014

Abstract

The significance of melanoma differentiation-associated gene-7/interleukin-24 (MDA-7/IL-24) expression in head and neck squamous cell carcinoma (HNSCC) remains unclear. This study was designed to investigate and evaluate the clinical significance of MDA-7/IL-24 expression in HNSCC by detecting expression by immunostaining in 131 HNSCC specimens. The function of MDA-7/IL-24 was investigated by real-time polymerase chain reaction (PCR) and Western blot in Ad5.mda-7-infected HNSCC cell lines. Our results showed that MDA-7/IL-24 was mainly expressed in the cytoplasm of HNSCC cells. MDA-7/IL-24 high patients presented with a favorable postoperative prognosis compared with MDA-7/IL-24 low patients, and high expression of MDA-7/IL-24 was significantly correlated with a lower incidence of second primary malignancies (SPMs) in the head and neck regions. In vitro assays showed that high expression of MDA-7/IL-24 could upregulate the expression of the epithelial terminal differentiation markers cytokeratin (KRT) 1, KRT4, KRT13, phosphorylated endoplasmic reticulum stress protein (p)-EIF2a, and the apoptosis-related protein cleaved caspase-3. It also downregulated the epithelial proliferative markers KRT5, KRT14, Integrin β4, and anti-apoptosis protein Bcl-2, which might be partially involved in the underlying mechanisms of Ad.mda-7-mediated HNSCC differentiation and apoptosis. Our results indicate that MDA-7/IL-24 can be a prognostic biomarker and an indicator of second primary malignancies (SPM) in HNSCC.

Available only for authorised users

Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108. doi:10.3322/canjclin.55.2.74.PubMedCrossRef

Bose P, Brockton NT, Dort JC. Head and neck cancer: from anatomy to biology. Int J Cancer. 2013;133(9):2013–23. doi:10.1002/ijc.28112.PubMedCrossRef

Leon X, Quer M, Diez S, Orus C, Lopez-Pousa A, Burgues J. Second neoplasm in patients with head and neck cancer. Head Neck. 1999;21(3):204–10.PubMedCrossRef

Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol. 2004;22:929–79. doi:10.1146/annurev.immunol.22.012703.104622.PubMedCrossRef

Jiang H, Lin JJ, Su ZZ, Goldstein NI, Fisher PB. Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene. 1995;11(12):2477–86.PubMed

Ellerhorst JA, Prieto VG, Ekmekcioglu S, Broemeling L, Yekell S, Chada S, et al. Loss of MDA-7 expression with progression of melanoma. J Clin Oncol. 2002;20(4):1069–74.PubMedCrossRef

Jiang H, Su ZZ, Lin JJ, Goldstein NI, Young CS, Fisher PB. The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. Proc Natl Acad Sci U S A. 1996;93(17):9160–5.PubMedCentralPubMedCrossRef

Su ZZ, Madireddi MT, Lin JJ, Young CS, Kitada S, Reed JC, et al. The cancer growth suppressor gene mda-7 selectively induces apoptosis in human breast cancer cells and inhibits tumor growth in nude mice. Proc Natl Acad Sci U S A. 1998;95(24):14400–5.PubMedCentralPubMedCrossRef

Wei L, Wang Z, Cui T, Yi F, Bu Y, Ding S, et al. Proteomic analysis of cervical cancer cells treated with adenovirus-mediated MDA-7. Cancer Biol Ther. 2008;7(4):510–6.PubMedCrossRef

10.

Hamed HA, Yacoub A, Park MA, Eulitt PJ, Dash R, Sarkar D, et al. Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant glioma. Mol Ther. 2010;18(6):1130–42.PubMedCentralPubMedCrossRef

11.

Saeki T, Mhashilkar A, Swanson X, Zou-Yang XH, Sieger K, Kawabe S, et al. Inhibition of human lung cancer growth following adenovirus-mediated mda-7 gene expression in vivo. Oncogene. 2002;21(29):4558–66. doi:10.1038/sj.onc.1205553.PubMedCrossRef

12.

Bhutia SK, Das SK, Kegelman TP, Azab B, Dash R, Su ZZ, et al. mda-7/IL-24 differentially regulates soluble and nuclear clusterin in prostate cancer. J Cell Physiol. 2012;227(5):1805–13. doi:10.1002/jcp.22904.PubMedCentralPubMedCrossRef

13.

Dent P, Yacoub A, Hamed HA, Park MA, Dash R, Bhutia SK, et al. MDA-7/IL-24 as a cancer therapeutic: from bench to bedside. Anti-Cancer Drugs. 2010;21(8):725–31. doi:10.1097/CAD.0b013e32833cfbe1.PubMedCentralPubMedCrossRef

14.

Feng Z, Li JN, Wang L, Pu YF, Wang Y, Guo CB. The prognostic value of glycerol-3-phosphate dehydrogenase 1-like expression in head and neck squamous cell carcinoma. Histopathology. 2014;64(3):348–55. doi:10.1111/his.12258.PubMedCrossRef

15.

Warren S, Gates O. Multiple primary malignant tumors. A survey of the literature and a statistical study. Am J Cancer. 1932;16:1358–414.

16.

Morris LG, Sikora AG, Patel SG, Hayes RB, Ganly I. Second primary cancers after an index head and neck cancer: subsite-specific trends in the era of human papillomavirus-associated oropharyngeal cancer. J Clin Oncol : Off J Am Soc Clin Oncol. 2011;29(6):739–46. doi:10.1200/JCO.2010.31.8311.CrossRef

17.

Ishikawa S, Nakagawa T, Miyahara R, Kawano Y, Takenaka K, Yanagihara K, et al. Expression of MDA-7/IL-24 and its clinical significance in resected non-small cell lung cancer. Clin Cancer Res : Off J Am Assoc Cancer Res. 2005;11(3):1198–202.

18.

Wang L, Wang Y, Bian H, Pu Y, Guo C. Molecular characteristics of homologous salivary adenoid cystic carcinoma cell lines with different lung metastasis ability. Oncol Rep. 2013;30(1):207–12. doi:10.3892/or.2013.2460.PubMed

19.

Vikram B. Changing patterns of failure in advanced head and neck cancer. Arch Otolaryngol. 1984;110(9):564–5.PubMedCrossRef

20.

Garavello W, Ciardo A, Spreafico R, Gaini RM. Risk factors for distant metastases in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2006;132(7):762–6. doi:10.1001/archotol.132.7.762.PubMedCrossRef

21.

Rennemo E, Zatterstrom U, Boysen M. Impact of second primary tumors on survival in head and neck cancer: an analysis of 2,063 cases. Laryngoscope. 2008;118(8):1350–6. doi:10.1097/MLG.0b013e318172ef9a.PubMedCrossRef

22.

Lin K, Patel SG, Chu PY, Matsuo JM, Singh B, Wong RJ, et al. Second primary malignancy of the aerodigestive tract in patients treated for cancer of the oral cavity and larynx. Head Neck. 2005;27(12):1042–8. doi:10.1002/hed.20272.PubMedCrossRef

23.

Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer. 1953;6(5):963–8.PubMedCrossRef

24.

Moll R, Divo M, Langbein L. The human keratins: biology and pathology. Histochem Cell Biol. 2008;129(6):705–33. doi:10.1007/s00418-008-0435-6.PubMedCentralPubMedCrossRef

25.

Knosel T, Emde V, Schluns K, Schlag PM, Dietel M, Petersen I. Cytokeratin profiles identify diagnostic signatures in colorectal cancer using multiplex analysis of tissue microarrays. Cell Oncol : Off J Int Soc Cell Oncol. 2006;28(4):167–75.

26.

Vaidya MM, Kanojia D. Keratins: markers of cell differentiation or regulators of cell differentiation? J Biosci. 2007;32(4):629–34.PubMedCrossRef

27.

Fuchs E, Green H. Changes in keratin gene expression during terminal differentiation of the keratinocyte. Cell. 1980;19(4):1033–42.PubMedCrossRef

28.

Margadant C, Charafeddine RA, Sonnenberg A. Unique and redundant functions of integrins in the epidermis. FASEB J : Off Publ Fed Am Soc Exp Biol. 2010;24(11):4133–52. doi:10.1096/fj.09-151449.CrossRef

29.

Lebedeva IV, Su ZZ, Vozhilla N, Chatman L, Sarkar D, Dent P, et al. Mechanism of in vitro pancreatic cancer cell growth inhibition by melanoma differentiation-associated gene-7/interleukin-24 and perillyl alcohol. Cancer Res. 2008;68(18):7439–47. doi:10.1158/0008-5472.CAN-08-0072.PubMedCentralPubMedCrossRef

30.

Yacoub A, Park MA, Gupta P, Rahmani M, Zhang G, Hamed H, et al. Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells. Mol Cancer Ther. 2008;7(2):297–313. doi:10.1158/1535-7163.MCT-07-2166.PubMedCentralPubMedCrossRef

31.

Yacoub A, Hamed HA, Allegood J, Mitchell C, Spiegel S, Lesniak MS, et al. PERK-dependent regulation of ceramide synthase 6 and thioredoxin play a key role in mda-7/IL-24-induced killing of primary human glioblastoma multiforme cells. Cancer Res. 2010;70(3):1120–9. doi:10.1158/0008-5472.CAN-09-4043.PubMedCentralPubMedCrossRef

32.

Gupta P, Walter MR, Su ZZ, Lebedeva IV, Emdad L, Randolph A, et al. BiP/GRP78 is an intracellular target for MDA-7/IL-24 induction of cancer-specific apoptosis. Cancer Res. 2006;66(16):8182–91. doi:10.1158/0008-5472.CAN-06-0577.PubMedCrossRef

33.

Yacoub A, Liu R, Park MA, Hamed HA, Dash R, Schramm DN, et al. Cisplatin enhances protein kinase R-like endoplasmic reticulum kinase- and CD95-dependent melanoma differentiation-associated gene-7/interleukin-24-induced killing in ovarian carcinoma cells. Mol Pharmacol. 2010;77(2):298–310. doi:10.1124/mol.109.061820.PubMedCentralPubMedCrossRef

34.

Lebedeva IV, Sarkar D, Su ZZ, Kitada S, Dent P, Stein CA, et al. Bcl-2 and Bcl-x(L) differentially protect human prostate cancer cells from induction of apoptosis by melanoma differentiation associated gene-7, mda-7/IL-24. Oncogene. 2003;22(54):8758–73. doi:10.1038/sj.onc.12068911206891.PubMedCrossRef

Title: Melanoma differentiation-associated gene-7/interleukin-24 as a potential prognostic biomarker and second primary malignancy indicator in head and neck squamous cell carcinoma patients
Authors: Lin Wang
Zhien Feng
Huanhuan Wu
Shuai Zhang
Yinfei Pu
Huan Bian
Yixiang Wang
Chuanbin Guo
Publication date: 01-11-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 11/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-2392-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2014

TES was epigenetically silenced and suppressed the epithelial–mesenchymal transition in breast cancer

New insights in cellular and molecular aspects of BM niche in chronic myelogenous leukemia

Designing a recombinant chimeric construct contain MUC1 and HER2 extracellular domain for prediagnostic breast cancer

Role of microRNA-93 in regulation of angiogenesis

A functional and protein-protein interaction analysis of neuroepithelial cell transforming gene 1 in hepatocellular carcinoma

Overexpression of CPS1 is an independent negative prognosticator in rectal cancers receiving concurrent chemoradiotherapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer